Electronic supplementary information

First one-pot stereoselective synthesis of *cis*-2,3-dihydro-4-perfluoroalkyl -1*H*-1,5-benzodiazepines *via* a catalyst-free three-component reaction

Jiechao Xu,^a Jiamei Wei,^a Linglin Bian,^a Jiaping Zhang,^a Jie Chen,^a Hongmei Deng,^a Xiaoyu Wu^{*a} Hui Zhang^{*a} and Weiguo Cao^{*a,b,c}

^a Department of Chemistry, Shanghai University, 99 Shangda Rd, Shanghai 200444, People's Republic of China. E-mail: wgcao@staff.shu.edu.cn, yehao7171@shu.edu.cn, wuxy@shu.edu.cn; Fax: (+86)-21-66134856

^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China

^c Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China

Experimental Section

General information

All reagents and solvents were purchased from commercial sources and used without further purification, except methyl 2-perfluoroalkynoates **2** were prepared according to reported literature. Melting points were uncorrected. ¹H, ¹⁹F and ¹³C NMR spectra were recorded on 500MHz spectrometer. All chemical shifts are reported in parts per million downfield (positive) of the standard: C_6F_6 for ¹⁹F, TMS for ¹H and ¹³C NMR spectra. IR spectras were obtained on a FT-IR spectrometer. Elemental analysis was performed on an elemental analysis instrument. MS (ESI) was run on a mass spectrometer and MS (EI) on a mass spectrometer. X-ray analysis was performed on an X-ray spectrometer.

Synthesis of product 3a.

A mixtrure of *o*-phenylenediamine **1** (0.5 mmol), methyl 2-perfluoroalkynoates **2a** (0.5 mmol) in anhydrous ethanol (5 mL) was stirred at room temperature for about 30 min. The completion of the reaction was monitored by TLC. The solvent was removed under vaccum. The residue was purified by silica gel column chromatography eluted with petroleum ether:ethyl acetate (v:v = 20:1) to give product **3a**.

$$\begin{array}{c} F_{3}C & OMe \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ &$$

(*Z*)-Methyl 3-(2-aminophenylamino)-4,4,4-trifluorobut-2-enoate **3a**: Yellow solid. Yield: 88%. M.p.: 120.1~120.2 °C. Anal. Calcd. for C₁₁H₁₁F₃N₂O₂: C, 50.77; H, 4.26; N, 10.77. Found C, 50.98; H, 4.47; N, 10.80. IR (KBr, cm⁻¹): *v* 1669 (C=O), 2952 (CH), 3030 (Ar-H), 3386 (NH₂), 3473 (NH). ¹H NMR (CDCl₃, ppm): δ 3.76 (s, 3H, OCH₃), 3.86 (s, 2H, NH), 5.39 (s, 1H, CH), 6.69-7.12 (m, 4H, ArH), 9.25 (s, 1H, NH). ¹³C NMR (CDCl₃, ppm): δ 170.2, 149.0 (q, CCF₃, ²*J*_{C-F} = 31.0 Hz), 144.1, 129.6, 129.5, 129.0, 123.8, 120.2 (q, CF₃, ¹*J*_{C-F} = 276.0 Hz), 118.2, 115.8, 88.5 (q, C=CCF₃, ³*J*_{C-F} = 6.2 Hz), 51.5. ¹⁹F NMR (CDCl₃, ppm): δ -65.5 (s, CF₃). ESI-MS (m/z): 260 (M⁺).

Synthesis of product 4a.

A mixture of *o*-phenylenediamine **1** (0.5 mmol), methyl 2-perfluoroalkynoates **2a** (0.5 mmol) in anhydrous ethanol (5 mL) was stirred at refluxing temperature for about 24h. The completion of the reaction was monitored by TLC. When the reaction finished, the solvent was removed by vaccum. The residue was purified by silica gel column chromatography eluted with petroleum ether:ethyl acetate (v:v = 10:1) to afford product **4a**.

$$(\mathbf{r}_{N}) \in \mathbf{r}_{0}^{\mathsf{N}}$$

(*E*)-4-(Trifluoromethyl)-1*H*-benzo[*b*][1,4]diazepin-2(*3H*)-one **4a**: Yellow solid. Yield: 73%. M.p.: 188.9~190.4°C. ¹H NMR (CDCl₃, ppm): δ 3.36 (s, 2H, CH₂), 7.15-7.51 (m, 4H, ArH), 9.37 (s, 1H, NH).

Synthesis of products 6.

General method: A mixture of *o*-phenylenediamine **1** (0.5 mmol), aldehydes **5** (0.5 mmol) and methyl 2-perfluoroalkynoates **2** (0.5 mmol) in anhydrous ethanol (5 mL) was stirred at refluxing temperature for about 20~24h. The completion of the reaction was monitored by TLC. When the reaction finished, the solvent was removed by vaccum. And the residue was purified by silica gel column chromatography eluted with petroleum ether:ethyl acetate (v:v = 10:1) to get product **6**. Futher purification could be carried out by recrystallization from petroleum ether:ethyl acetate (v:v = 2:1).



6a

cis-Methyl 2-(2-bromophenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6a:** Yellow solid. Yield: 57%. M.p.: 150.9~153.5 °C . Anal. Calcd. for $C_{18}H_{14}BrF_3N_2O_2$: C, 50.61; H, 3.30; N, 6.56. Found: C, 50.68; H, 3.24; N, 6.73. IR (KBr, cm⁻¹): *v* 1724 (C=O); 2953 (C-H); 3046 (Ar-H); 3427 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.56 (s, 3H, OCH₃), 4.46 (d, *J* = 4.5 Hz, 1H, CH), 4.62 (d, *J* = 6.0 Hz, 1H, NH), 4.83 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.75-7.67 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 166.7, 145.4 (q, CCF₃, ²*J*_{C-F} = 34 Hz) , 141.8, 138.1, 136.8, 133.8, 131.1, 130.3, 129.3, 128.0, 127.3, 120.5 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 119.9, 118.4, 117.6, 56.1, 55.3, 52.6. ¹⁹F NMR (CDCl₃, ppm): δ -71.39 (s, CF₃). ESI-MS (m/z): 426 (M⁺).



6b

cis-Methyl 2-(4-bromophenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6b**: Yellow solid. Yield: 73%. M.p.: 135.9~138.3 °C. Anal. Calcd. for C₁₈H₁₄BrF₃N₂O₂: C, 50.61; H, 3.30; N, 6.56. Found: C, 50.90; H, 3.43; N, 6.81. IR (KBr, cm⁻¹): *v* 1750 (C=O); 2957 (C-H); 3051 (Ar-H); 3329 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.58 (s, 3H, OCH₃), 4.44 (d, *J* = 4.5 Hz, 1H, CH), 4.94 (d, *J* = 6.0 Hz, 1H, NH), 5.44 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.76-7.44 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.6, 147.0 (q, CF₃, ²*J*_{C-F} = 34 Hz), 140.8, 139.8, 134.7, 131.9, 130.7, 130.3, 127.4, 121.9, 120.0 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 119.4, 118.3, 77.1, 60.6, 54.2, 53.1. ¹⁹F NMR (CDCl₃, ppm): δ -71.69 (s, CF₃). ESI-MS (m/z): 426 (M⁺).



cis-Methyl 2-*p*-tolyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3-carboxylate **6c**: Yellow solid. Yield: 90%. M.p.: 148.6~148.9°C. Anal. Calcd. for C₁₉H₁₇F₃N₂O₂: C, 62.98; H, 4.73; N, 7.73. Found: C, 62.81; H, 4.56; N, 7.82. IR (KBr, cm⁻¹): *v* 1745 (C=O); 2957 (C-H); 3080 (Ar-H); 3329 (N-H). ¹H NMR (CDCl₃, ppm): δ 2.27 (s, 3H, CH₃), 3.58 (s, 3H, OCH₃), 4.47 (d, *J* = 4.5 Hz, 1H, CH), 4.94 (d, *J* = 6.0 Hz, 1H, NH), 5.39 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.73-7.44 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.2, 147.0 (q, CF₃, ²*J*_{C-F} = 34 Hz), 141.6, 138.0, 137.8, 135.0, 130.8, 130.4, 129.6, 125.7, 122.5, 120.7, 120.1 (q, CF₃, ¹*J*_{C-F} = 267.5 Hz), 119.0, 118.4, 60.6, 54.9, 53.1, 21.2. ¹⁹F NMR (CDCl₃, ppm): δ -71.54 (s, CF₃). ESI-MS (m/z): 362 (M⁺).



6d

cis-Methyl 2-(4-fluorophenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6d:** Yellow solid. Yield: 54%. M.p.: 95.1~96.1°C. Anal. Calcd. for C₁₈H₁₄F₄N₂O₂: C, 59.02; H, 3.85; N, 7.65. Found: C, 59.09; H, 3.56; N, 7.82. IR (KBr, cm⁻¹): v = 1745 (C=O); 2959 (C-H); 3080 (Ar-H); 3335 (N-H). ¹H NMR (CDCl₃, ppm): $\delta = 3.55$ (s, 3H, OCH₃), 4.44 (d, *J* =4.5 Hz, 1H, CH), 5.09 (d, *J* =6.5 Hz, 1H, NH), 5.44 (dd, *J*₁ = 6.5 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.73-7.43 (m, 8H, ArH). ¹³C-NMR (CDCl₃, ppm): δ 167.7, 163.2, 161.2, 146.8 (q, CF₃, ²*J*_{C-F} =34 Hz), 141.1, 136.8 (d, Ar-F, ²*J*_{C-F} =2.5 Hz), 134.7, 130.7, 130.2, 127.4 (d, Ar-F, ¹*J*_{C-F} =7.5 Hz), 119.9 (q, CF₃, ¹*J*_{C-F} =276 Hz), 119.2, 118.3, 115.7, 115.6, 60.4, 54.5, 53.0. ¹⁹F NMR (CDCl₃, ppm): δ -71.67 (s, CF₃), -114.22 (m, ArF). ESI-MS (m/z): 366 (M⁺).



6e

cis-Methyl 2-(4-methoxyphenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6e:** Yellow solid. Yield: 80%. M.p.: 110.7~111.2°C. Anal. Calcd. for C₁₉H₁₇F₃N₂O₃: C, 60.32; H, 4.53; N, 7.40. Found: C, 57.91; H, 4.43; N, 7.17. IR (KBr, cm⁻¹): *v* 1736 (C=O); 2956 (C-H); 3004 (Ar-H); 3398 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.58 (s, 3H, OCH₃), 3.73 (s, 3H, OCH₃), 4.44 (d, *J* = 4.5 Hz, 1H, CH), 4.95 (d, *J* = 4.0 Hz, 1H, NH), 5.38 (dd, *J*₁ = 4.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.74-7.44 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.0, 159.1, 146.8 (q, CF₃, ²*J*_{C-F} = 34 Hz), 141.6, 134.9, 133.0, 132.1, 130.7, 130.1, 126.9, 120.1 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 118.9, 118.3, 114.1, 114.5, 59.9, 55.2, 54.9, 53.0. ¹⁹F NMR (CDCl₃, ppm): δ -71.39 (s, CF₃). ESI-MS (m/z): 378 (M⁺).



cis-Methyl 2-(4-nitrophenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6f:** Yellow solid. Yield: 50%. M.p.: 176.5~180.0°C. Anal. Calcd. for C₁₈H₁₄F₃N₃O₄: C, 54.97; H, 3.59; N, 10.68. Found: C, 54.99; H: 3.35; N: 10.89. IR (KBr, cm⁻¹): *v* 1743 (C=O); 2971 (C-H); 3079 (Ar-H); 3375 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.61 (s, 3H, OCH₃), 4.36 (d, *J* = 4.0 Hz, 1H, CH), 4.65 (d, *J* = 6.0 Hz, 1H, NH), 4.70 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.0 Hz, 1H, CH), 6.78-8.31 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 166.4, 148.2, 146.4, 145.5 (q, CF₃, ²*J*_{C-F} = 34 Hz), 140.9, 136.4, 131.3, 129.6, 128.2, 124.4, 120.4, 120.3 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 120.1, 118.6, 113.4, 58.1, 56.6, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -71.57 (s, CF₃). ESI-MS (m/z): 393 (M⁺).



6g

cis-Methyl 2-phenyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3-carboxylate **6g:** Yellow solid. Yield: 72%. M.p.: 113.8~114.2°C. Anal. Calcd. for C₁₈H₁₅F₃N₂O₂: C, 62.07; H, 4.34; N, 8.04. Found: C, 61.80; H, 4.12; N, 8.02. IR (KBr, cm⁻¹): *v* 1742 (C=O); 2957 (C-H); 3075 (Ar-H); 3309 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.59 (s, 3H, OCH₃), 4.47 (d, *J* = 4.0 Hz, 1H, CH), 4.92 (d, *J* = 6.0 Hz, 1H, NH), 5.47 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.0 Hz, 1H, CH), 6.77-7.45 (m, 9H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.9, 146.8 (q, CF₃, ²*J*_{C-F} = 34 Hz), 141.4, 140.9, 138.4, 134.8, 130.7, 130.2, 128.8, 127.9, 125.6, 119.9 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 119.7, 119.0, 118.3, 60.8, 54.7, 53.0. ¹⁹F NMR (CDCl₃, ppm): δ -71.74 (s, CF₃). ESI-MS (m/z): 348 (M⁺).



cis-Methyl 2-(1*H*-indol-3-yl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6h:** Yellow solid. Yield: 56%. M.p.: 149.4~152.0 °C. Anal. Calcd. for C₂₀H₁₆F₃N₃O₂: C, 62.01; H, 4.16; N, 10.85. Found: C, 61.74; H, 3.94; N, 10.87. IR (KBr, cm⁻¹): *v* 1747 (C=O); 2956 (C-H); 3063 (Ar-H); 3388 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.67 (s, 3H, OCH₃), 4.60 (d, *J* = 4.0 Hz, 1H, CH), 4.99 (d, *J* = 6.0 Hz, 1H, NH), 5.66 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.0 Hz, 1H, CH), 6.70-7.97 (m, 10H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.6, , 147.2 (q, CF₃, ²*J*_{C-F} = 34 Hz), 141.9, 136.6, 136.1, 135.4, 132.2, 131.1, 130.8, 129.1, 124.9, 124.7, 120.4 (q, CF₃, ¹*J*_{C-F} = 273 Hz), 120.2, 118.6, 115.9, 111.7, 54.9, 53.2, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -71.34 (s, CF₃). ESI-MS (m/z): 387 (M⁺).

cis-Methyl 2-*n*-heptyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3-carboxylate **6i:** Yellow oil. Yield: 56%. Anal. Calcd. for C₁₉H₂₅F₃N₂O₂: C, 61.61; H, 6.80; N, 7.56. Found: C, 61.43; H, 6.67; N, 7.53. IR (KBr, cm⁻¹): *v* 1737 (C=O); 2928 (C-H); 3065 (Ar-H); 3398 (N-H). ¹H NMR (CDCl₃, ppm): δ 0.84 (t, *J* = 7.0, 3H, CH₃), 1.19~1.28 (m, 12H, C₆H₁₂), 3.62 (s, 3H, OCH₃), 3.99 (m, 1H, CH), 4.17 (d, *J* = 4.0 Hz, 1H, NH), 4.89 (d, *J* = 5.5 Hz, 1H, CH), 6.64-7.56 (m, 4H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.9, 144.5 (q, CF₃, ²*J*_{C-F} = 34 Hz), 141.0, 136.3, 131.0, 129.5, 120.5 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 118.7, 118.4, 117.4, 54.9, 53.0, 52.8, 32.7, 31.6, 29.0, 26.0, 22.6, 14.0. ¹⁹F NMR (CDCl₃, ppm): δ -71.26 (s, CF₃). ESI-MS (m/z): 370 (M⁺).



6j

cis-Methyl 2-cyclohexyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6j**: Yellow solid. Yield: 68%. M.p.: 126.6~127.2°C. Anal. Calcd. for C₁₈H₂₁F₃N₂O₂: C, 61.01; H, 5.97; N, 7.91. Found: C, 61.30; H, 6.01; N, 8.01. IR (KBr, cm⁻¹): *v* 1735 (C=O); 2960 (C-H); 3060 (Ar-H); 3403 (N-H). ¹H NMR (CDCl₃, ppm): δ 0.88-1.76 (m, 11H, C₆H₁₁), 2.10 (dd, $J_1 = 4.0, J_2 = 3.5, 1H, CH$), 3.62 (s, 3H, CH₃), 4.39 (d, J = 4.0 Hz, 1H, CH), 4.90 (d, J = 3.5 Hz, 1H, NH), 6.64-7.54 (m, 4H, ArH). ¹³C NMR (CDCl₃, ppm): δ 169.6, 144.8 (q, CF₃, ² $J_{C-F} = 34$ Hz), 141.5, 136.7, 131.4, 129.9, 120.7 (q, CF3, ¹ $J_{C-F} = 276$ Hz), 118.9, 116.2, 58.2, 53.0, 52.3, 39.1, 29.9, 29.4, 26.2, 25.8, 25.7. ¹⁹F NMR (CDCl₃, ppm): δ -70.65 (s, CF₃). ESI-MS (m/z): 354 (M⁺).



6k

cis-Methyl 2-(naphthalen-1-yl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6k:** Yellow solid. Yield: 85%. M.p.: 204.3~206.4 °C. Anal. Calcd. for $C_{22}H_{17}F_3N_2O_2$: C, 66.33; H, 4.30; N, 7.03. Found: C, 66.07; H, 4.04; N, 7.15. IR (KBr, cm⁻¹): *v* 1739 (C=O); 2960 (C-H); 3059 (Ar-H); 3405 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.57 (s, 3H, OCH₃), 4.51 (d, *J* = 3.5 Hz, 1H, CH), 4.76 (d, *J* = 6.0 Hz, 1H, NH), 6.39 (dd, *J*₁ = 6.0 Hz, *J*₂ = 3.5 Hz, 1H, CH), 6.81-7.80 (m, 11H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.8, 147.1 (q, CF₃, ²*J*_{C-F} = 34 Hz), 143.7, 138.8, 134.9, 134.8, 131.1, 130.4, 130.1, 130.0, 129.4, 127.8, 126.7, 126.1, 124.6, 122.5, 120.9 (q, CF₃, ¹*J*_{C-F} = 275 Hz), 119.3, 118.5, 60.3, 53.5, 20.8. ¹⁹F NMR (CDCl₃, ppm): δ -71.39 (s, CF₃). ESI-MS (m/z): 398 (M⁺).



61

cis-Methyl 2-(furan-2-yl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **61:** Yellow solid. Yield: 81%. M.p.: 88.1~89.7 °C. Anal. Calcd. for C₁₆H₁₃F₃N₂O₃: C, 56.81; H, 3.87; N, 8.28. Found: C, 56.70; H, 3.69; N, 8.37. IR (KBr, cm⁻¹): *v* 1730 (C=O); 2959 (C-H); 3034 (Ar-H); 3412 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.65 (s, 3H, OCH₃), 4.66 (d, *J* = 4.0 Hz, 1H, CH), 5.04 (d, *J* = 5.5 Hz, 1H, NH), 5.33 (dd, *J*₁ = 5.5 Hz, *J*₂ = 4.0 Hz, 1H, CH), 5.92 (d, *J*₂ = 1.5 Hz, 1H, Furan-H), 6.15 (dd, *J*₁ = 4 Hz, *J*₂ = 1.5 Hz, 1H, Furan-H), 6.72-7.47 (m, 4H, ArH), 7.46 (d, *J* = 4 Hz, 1H, Furan-H). ¹³C NMR (CDCl₃, ppm): δ 168.1, 151.9, 145.7 (q, CF₃, ²*J*_{C-F} = 34 Hz), 142.3, 141.1, 135.9, 131.1, 128.8, 120.4 (q, CF₃, ¹*J*_{C-F} = 275 Hz), 119.7, 118.5, 113.1, 110.6, 107.4, 53.4, 52.6. ¹⁹F NMR (CDCl₃, ppm): δ -71.40 (s, CF₃). ESI-MS (m/z): 338 (M⁺).



6m

methyl 2-(4-methoxyphenyl)-7,8-dimethyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4] diazepine-3-carboxylate **6m**: Yellow solid. Yield: 62%. M.p.: 153.8~156.3 °C. Anal. Calcd. for C₂₁H₂₁F₃N₂O₃: C, 62.06; H, 5.21; N, 6.89. Found: C, 62.23; H, 5.33; N, 6.90. IR (KBr, cm⁻¹): *v* 1747 (C=O); 2953 (C-H); 3038 (Ar-H); 3393 (N-H). ¹H NMR (CDCl₃, ppm): δ 2.14 (s, 3H, CH₃), 2.18 (s, 3H, CH₃), 3.59 (s, 3H, OCH₃), 3.70 (s, 3H, OCH₃), 4.46 (d, *J* = 4.5 Hz, 1H, CH), 4.87 (d, *J* = 5.5 Hz, 1H, NH), 5.28 (dd, *J*₁ = 4.5 Hz, *J*₂ = 5.5 Hz, 1H, CH), 6.51-7.21 (m, 6H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.1, 159.0, 145.2 (q, CF₃, ²*J*_{C-F} = 34 Hz), 140.2, 139.3, 135.4, 133.1, 128.0, 127.2, 126.8, 120.2 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 118.9, 114.0, 59.0, 55.2, 54.8, 52.9, 19.6, 18.3. ¹⁹F NMR (CDCl₃, ppm): δ -71.24 (s, CF₃). ESI-MS (m/z): 406 (M⁺).



6n

methyl 7,8-dichloro-2-(4-methoxyphenyl)-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4] diazepine-3-carboxylate **6n**: Yellow oil. Yield: 60%. Anal. Calcd. for C₁₉H₁₅C₁₂F₃N₂O₃: C, 51.03; H, 3.38; N, 6.26. Found: C, 51.22; H, 3.40; N, 6.28. IR (KBr, cm⁻¹): *v* 1738 (C=O); 2956 (C-H); 3064 (Ar-H); 3392 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.63 (s, 3H, OCH₃), 3.72 (s, 3H, OCH₃), 4.52 (d, *J* = 5.0 Hz, 1H, CH), 5,31 (dd, *J*₁ = 5.0 Hz, *J*₂ = 5.5 Hz, 1H, CH), 5.41 (br-s, 1H, NH), 6.76-7.53 (m, 6H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.6, 159.4, 148.2 (q, CF₃, ²*J*_{C-F} = 35 Hz), 141.2, 136.1, 134.2, 132.2, 130.6, 129.3, 126.7, 121.4, 119.8 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 118.9, 114.4, 60.6, 58.9, 55.4, 53.3, 21.2, 14.3. ¹⁹F NMR (CDCl₃, ppm): δ -71.79 (s, CF₃). ESI-MS (m/z): 446 (M⁺).



cis-Methyl 2-(4-nitrophenyl)-4-(pentafluoroethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **60:** Yellow solid. Yield: 31%. M.p.: 150.4~151.1°C. Anal. Calcd. for C₁₉H₁₄F₅N₃O₄: C, 51.48; H, 3.18; N, 9.48. Found: C, 51.24; H, 3.34; N, 9.57. IR (KBr, cm⁻¹): *v* 1741 (C=O); 2956 (C-H); 3080 (Ar-H); 3421 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.59 (s, 3H, OCH₃), 4.53 (d, *J* = 4.5 Hz, 1H, CH), 5.03 (d, *J* = 6.5 Hz, 1H, NH), 5.66 (dd, *J*₁ = 6.5 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.82-8.14 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.4, 148.2, 147.5, 147.2, 146.9, 140.4, 134.9, 131.2, 130.6, 126.9, 124.1, 120.0, 119.7, 118.3, 118.2 (qt, CF₃, ¹*J*_{C-F} = 270 Hz, ²*J*_{C-F} = 36 Hz), 109.4 (m, CF₂), 61.3, 53.9, 53.3. ¹⁹F NMR (CDCl₃, ppm): δ -80.77 (s, CF₃), -114.19 (m, CF₂). ESI-MS (m/z): 443 (M⁺).



cis-Methyl 4-(pentafluoroethyl)-2-*p*-tolyl-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3-carboxylate **6p:** Yellow solid. Yield: 61%. M.p.: 109.6~112.2°C. Anal. Calcd. for C₂₀H₁₇F₅N₂O₂: C, 58.25; H, 4.16; N, 6.79. Found: C, 58.34; H, 4.34; N, 6.81. IR (KBr, cm⁻¹): *v* 1720 (C=O); 2955 (C-H); 3037 (Ar-H); 3381 (N-H). ¹H NMR (CDCl₃, ppm): δ 2.27 (s, 3H, CH₃), 3.57 (s, 3H, OCH₃), 4.51 (d, *J* = 4.5 Hz, 1H, CH), 4.95 (d, *J* = 6.0 Hz, 1H, NH), 5.41 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.72-7.42 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.1, 147.5, 147.2, 141.5, 138.1, 137.7, 135.2, 130.8, 130.5, 129.4, 125.6, 122.5, 119.6, 118.9, 118.1, 118.8 (qt, CF₃, ¹*J*_{C-F} = 285 Hz, ²*J*_{C-F} = 36 Hz), 110.4 (m, CF₂), 60.5, 54.7, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -80.78 (s, CF₃), -114.14 (m, CF₂). ESI-MS (m/z): 412 (M⁺).



cis-Methyl 2-(4-methoxyphenyl)-4-(pentafluoroethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6q:** Yellow solid. Yield: 51%. M.p.: 100.3~103.3 °C. Anal. Calcd. for C₂₀H₁₇F₅N₂O₃: C, 56.08; H, 4.00; N, 6.54. Found: C, 56.26; H, 4.22; N, 6.58. IR (KBr, cm⁻¹): *v* 1728 (C=O); 2957 (C-H); 3076 (Ar-H); 3335 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.58 (s, 3H, OCH₃), 3.74 (s, 3H, OCH₃), 4.47 (d, *J* = 5.0 Hz, 1H, CH), 4.96 (d, *J* = 6.0 Hz, 1H, NH), 5.40 (dd, *J*₁ = 6.0 Hz, *J*₂ = 5.0 Hz, 1H, CH), 6.73-7.43 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.1, 159.2, 147.6, 147.4, 141.4, 135.1, 133.3, 130.8, 130.5, 126.9, 125.6, 124.1, 118.9, 118.8 (qt, CF₃, ¹*J*_{C-F} = 259 Hz, ²*J*_{C-F} = 36 Hz), 118.2, 110.4 (m, CF₂), 60.4, 55.3, 54.8, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -80.79 (s, CF₃), -114.16 (m, CF₂). ESI-MS (m/z): 428 (M⁺).



cis-Methyl 2-(4-bromophenyl)-4-(pentafluoroethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6r**: Yellow solid. Yield: 71%. M.p.: 113.0~114.2°C. Anal. Calcd. for C₁₉H₁₄BrF₅N₂O₂: C, 47.82; H, 2.96; N, 5.87. Found: C, 47.96; H, 3.02; N, 5.96. IR (KBr, cm⁻¹): *v* 1724 (C=O); 2953 (C-H); 3096 (Ar-H); 3340 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.55 (s, 3H, OCH₃), 4.49 (d, *J* = 4.5 Hz, 1H, CH), 5.07 (d, *J* = 6.5 Hz, 1H, NH), 5.42 (dd, *J*₁ = 6.5 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.73-7.41 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.8, 147.4, 147.2, 140.5, 135.0, 131.9, 130.7, 128.7, 128.4, 127.5, 127.2, 126.1, 120.1, 118.7 (qt, CF₃, ¹*J*_{C-F} = 285 Hz, ²*J*_{C-F} = 36 Hz), 118.2, 110.4 (m, CF₂), 60.6, 54.2, 53.1. ¹⁹F NMR (CDCl₃, ppm): δ -80.73 (s, CF₃), -114.10 (m, CF₂). ESI-MS (m/z): 476 (M⁺).



cis-Methyl 2-(naphthalen-1-yl)-4-(*n*-heptafluoropropyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3-carboxylate **6s:** Yellow solid. Yield: 74%. M.p.: 129.5~130.0°C. Anal. Calcd. for C₂₄H₁₇F₇N₂O₂: C, 57.84; H, 3.44; N, 5.62. Found: C, 57.99; H, 3.67; N, 5.76. IR (KBr, cm⁻¹): *v* 1728 (C=O); 2956 (C-H); 3063 (Ar-H); 3381 (N-H). ¹H-NMR (CDCl₃, ppm): δ 3.58 (s, 3H, OCH₃), 4.75 (d, *J* = 4.5 Hz, 1H, CH), 4.99 (d, *J* = 6.0 Hz, 1H, NH), 6.35 (dd, *J*₁ = 6.0 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.76-8.04 (m, 11H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.0, 149.0, 141.4, 137.3, 136.9, 134.6, 133.8, 131.2, 130.3, 129.6, 129.1, 127.3, 126.0, 125.5, 124.2, 123.4, 121.6, 120.2 (qt, CF₃, ¹*J*_{C-F} = 286 Hz, ²*J*_{C-F} = 35 Hz), 119.6, 118.5, 110.4 (m, CF₂), 108.7 (m, CF₂), 61.3, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -79.65 (t, *J* = 9.4 Hz, CF₃), -112.95 (m, CF₂), -125.08 (m, CF₂). ESI-MS (m/z): 498 (M⁺).



cis-Methyl 2-(4-bromophenyl)-4-(*n*-heptafluoropropyl)-2,3-dihydro-1*H*-benzo[*b*][1,4]diazepine-3carboxylate **6t:** Yellow oil. Yield: 70%. Anal. Calcd. for C₂₀H₁₄BrF₇N₂O₂: C, 45.56; H, 2.68; N, 5.31. Found: C, 45.87; H, 2.88; N, 5.45. IR (KBr, cm⁻¹): *v* 1753 (C=O); 2960 (C-H); 3097 (Ar-H); 3345 (N-H). ¹H NMR (CDCl₃, ppm): δ 3.50 (s, 3H, OCH₃), 4.53 (d, *J* = 4.5 Hz, 1H, CH), 5.28 (d, *J* = 6.5 Hz, 1H, NH), 5.39 (dd, *J*₁ = 6.5 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.71-7.41 (m, 8H, ArH). ¹³C NMR (CDCl₃, ppm): δ 167.7, 147.5, 147.2, 141.2, 140.3, 134.9, 131.6, 131.0, 130.5, 128.7, 127.5, 118.8, 117.9, 115.5 (qt, CF₃, ¹*J*_{C-F} = 303 Hz, ²*J*_{C-F} = 36 Hz), 113.6, 110.6 (m, CF₂), 109.5 (m, CF₂), 60.5, 54.7, 52.9. ¹⁹F NMR (CDCl₃, ppm): δ -79.67 (t, *J* = 9.4 Hz, CF₃), -111.78 (m, CF₂), -124.64 (m, CF₂). ESI-MS (m/z): 526 (M⁺).



Methyl 2-(4-methoxyphenyl)-6-methyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4] diazepine-3-carboxylate **6u** and Methyl 2-(4-methoxyphenyl)-9-methyl-4-(trifluoromethyl)-2,3-dihydro-1*H*-benzo[*b*][1,4] diazepine-3-carboxylate **6u**': Yellow oil. Yield: 64%. Anal. Calcd. for C₂₀H₁₉F₃N₂O₃: C, 61.22; H, 4.88; N, 7.14. IR (KBr, cm⁻¹): *v* 1739 (C=O); 2956 (C-H); 3003 (Ar-H); 3399 (N-H). **6u** ¹H NMR (CDCl₃, ppm): δ 2.38 (s, 3H, CH₃), 3.53 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 4.17 (d, *J* = 4.5 Hz, 1H, CH), 4.36 (br-s, 1H, NH), 5.46 (dd, *J*₁ = 5 Hz, *J*₂ = 4.5 Hz, 1H, CH), 6.60-7.35 (m, 7H, ArH). **6u'** ¹H NMR (CDCl₃, ppm): δ 2.26 (s, 1H, CH₃), 3.58 (s, 1H, OCH₃), 3.74 (s, 1H, OCH₃), 4.46 (d, *J* = 4.5 Hz, 0.3H, CH), 4.74 (d, *J* = 5.5 Hz, 0.3H, NH), 5.50 (dd, *J*₁ = 4.5 Hz, *J*₂ = 5.5 Hz, 0.3H, CH), 6.60-7.35 (m, 2.1H, ArH). ¹³C NMR (CDCl₃, ppm): δ 168.3, 168.2, 159.4, 159.3, 148.4 (q, CF₃, ²*J*_{C-F} = 35 Hz), 147.0 (q, CF₃, ²*J*_{C-F} = 34 Hz), 140.7, 140.3, 139.7, 133.5, 133.0, 132.9, 132.2, 131.8, 131.5, 131.1, 129.8, 127.9, 127.4, 126.9, 124.6, 122.4, 120.1 (q, CF₃, ¹*J*_{C-F} = 276 Hz), 117.6, 114.5, 114.3, 114.2, 60.9, 60.6, 55.4, 55.3, 54.7, 54.2, 53.0, 52.9, 21.2, 19.2, 18.4, 14.4. ¹⁹F NMR (CDCl₃, ppm): δ -71.25 (s, CF₃), -71.37 (s, CF₃). ESI-MS (m/z): 392 (M⁺).













Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2011



















200 190

180 170

160

150 140 130

120 110 100 90 80 70 60 50 40 30 20 10



0 ppm













































1-1





6u'

6u



